SignaCor Therapeutics Secures €288k Investment to Advance Cardiovascular Health Innovation

SignaCor Therapeutics, a HealthTech startup based in Belfast, has secured €288k (£250k) in funding from VC firm Zinc to further develop a new treatment aimed at repairing heart damage and slowing down the progression of hypertrophic cardiomyopathy (HCM). This funding is part of the company’s overall Seed round, which is expected to reach €1.1 million (£1 million) by April.

CEO Darach Neeson expressed excitement about the investment, highlighting the value of the Discovery Park’s startup growth programme in influencing their strategy. The funding will enable SignaCor to advance their Phase 2a trial plans and regulatory strategy, bringing them closer to delivering a new treatment for patients with limited options.

The investment in SignaCor comes amidst continued investor activity in the cardiovascular innovation space across Europe. Other notable funding rounds include NanoPhoria Bioscience securing €83.5 million in Series A funding, Ultromics raising €48 million in Series C, and DESKi receiving €5.2 million in Seed funding. These investments highlight the ongoing interest in technologies addressing cardiovascular disease.

Programme Lead Renos Savva from Discovery Park emphasized the success of SignaCor as a result of combining scientific rigor with a supportive network. SignaCor, founded in 2024, is dedicated to developing treatments for HCM, a genetic cardiac disorder affecting around 1 in 500 people in the UK.

SignaCor’s innovative approach aims to reverse heart damage and improve the quality of life for patients with HCM. The company’s first-in-class treatment, ‘Cardiaza,’ harnesses DNA methylation to target the underlying causes of symptomatic HCM, including established fibrosis.

Natalie Pankova, Partner at Zinc, praised SignaCor’s scientific strength and clear path to clinical impact. The funding was delivered through Discovery Spark, a business growth programme focusing on life sciences. SignaCor was recognized as the overall winner for their standout pitch presentation and experienced team.

The importance of cardiovascular health was highlighted by the cohort’s focus on heart health, given that cardiovascular diseases account for 1 in 4 deaths in the UK. Another cohort of Discovery Spark is set to begin in mid-March with a focus on open tech.

Overall, SignaCor’s success reflects the growing interest and investment in innovative treatments for cardiovascular diseases. The company’s dedication to addressing the underlying disease pathology shows promise for improving outcomes for patients with HCM. Sure, here is the pure rewritten HTML ready for WordPress integration: